Ginkgo Bioworks Holdings DNA
NYSE DNA
$6.93 -0.02 (-0.27%)
As of: Sep 4, 2026 · 11:46 AM EDT

Ginkgo Bioworks Holdings (DNA) Non Operating Interest Expenses (2020 - 2024)

Analysis

Ginkgo Bioworks Holdings (DNA) Non Operating Interest Expenses (2020 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 140.12 Bn 132.26 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 86.04 Bn 78.04 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.63 Bn 58.45 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.45 Bn 52.31 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - 23.78 Mn
6 BeOne Medicines 40.14 Bn 35.04 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.29 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.62 Bn 27.79 Bn - 93.62 Mn
9 Insmed 27.73 Bn 26.57 Bn 358.27 Mn 20.27 Mn
10 Ginkgo Bioworks Holdings 430.93 Mn 346.40 Mn 18.44 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 31.37 Mn
Sep 30, 2024 -9.25 Mn
Jun 30, 2024 -10.31 Mn
Dec 31, 2023 44.01 Mn
Sep 30, 2023 -15.02 Mn
Jun 30, 2023 -14.35 Mn
Dec 31, 2021 551,000.00
Sep 30, 2021 649,000.00
Dec 31, 2020 590,000.00
Sep 30, 2020 592,000.00